interleukin-6 and chronic inflammation白细胞介素- 6和慢性炎症.pdfVIP

Available online /content/8/S2/S3 Proceedings Interleukin-6 and chronic inflammation Cem Gabay Division of Rheumatology, University Hospital of Geneva, and Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland Corresponding author: Cem Gabay, cem.gabay@hcuge.ch Published: 28 July 2006 Arthritis Research Therapy 2006, 8(Suppl 2):S3 This article is online at /content/8/S2/S3 (doi:10.1186/ar1917) © 2006 BioMed Central Ltd Abstract acute phase proteins (Figure 1), as well as numerous Interleukin (IL)-6 is produced at the site of inflammation and plays a behavioural, physiological, biochemical and nutritional key role in the acute phase response as defined by a variety of changes [4]. The acute phase proteins have been defined as clinical and biological features such as the production of acute a set of plasma proteins with concentrations that increase phase proteins. IL-6 in combination with its soluble receptor (positive acute phase proteins) or decrease (negative acute sIL-6Rα, dictates the transition from acute to chonic inflammation phase proteins) by at least 25% in inflammatory disorders by changing the nature of leucocyte infiltrate (from polymorpho- [4,5] (Figure 1). The changes in concentrations of acute nuclear neutrophils to monocyte/macrophages). In addition, IL-6 exerts stimulatory effects on T- and B-cells, thus favoring chronic phase proteins are largely due to changes in their production inflammatory responses.